NDARC’s Dr Ryan Courtney presented at the 2019 NDARC Seminar Series on Thursday, 9 May 2019.
The presentation was an update on an ongoing study that aims to evaluate the cost-effectiveness of cytisine compared to varenicline. The results of this study are intended to inform both Australian and international health agencies.
Cytisine is a well-tolerated smoking cessation treatment that is superior to placebo and nicotine replacement therapy. Like varenicline, cytisine is a nicotinic acetylcholine receptor partial agonist, yet has never been formally compared against varenicline.
Cytisine has the lowest cost per quality-adjusted-life-year of all smoking cessation medications, and modelling suggests cytisine may be more cost-effective than varenicline.
Findings from the Cytisine versus varenicline for smoking cessation trial are vital for informing policy makers around the world, given the opportunity for significant health-care system savings, particularly for low- and middle-income countries where most cessation medications are cost-prohibitive.
Dr Ryan Courney is a Senior Research Fellow and NHMRC Career Development Fellow at the National Drug and Alcohol Research Centre (NDARC). Dr Courtney leads the Tobacco Research Group and is a clinical trialist with expertise in smoking cessation and social disadvantage research.
The NDARC Seminar Series takes place every Thursday at 3.00pm. Members of the alcohol and other drug (AOD) sector and research community are welcome to attend.
2019 NDARC Seminar Series
Day and time: Every Thursday at 3.00pm
Location: Lecture Room 122, Building R1, 22 - 32 King St Randwick, NSW 2031
Cost: Free
Click here to register for upcoming NDARC seminars
For more information or booking enquiries please contact NDARC.Events@unsw.edu.au.